Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
Jiawei Yue1, Hui Guo2, Peng Xu1
1Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Cancer Immunology, Immunotherapy : CII
|March 2, 2024
Summary
Group 2 innate lymphoid cells (ILC2s) are quiescent in lung tumors but can be activated by IL-33. Combining IL-33 with anti-PD-1 therapy enhances anti-tumor immunity and immunotherapy efficacy.
Area of Science:
- Immunology
- Cancer Research
- Cell Biology
Background:
- Group 2 innate lymphoid cells (ILC2s) are key cytokine producers in tissues.
- Their role in cancer immunity and immunotherapy is not well understood.
Purpose of the Study:
- To investigate the role of ILC2s in lung adenocarcinoma (LUAD) immunity.
- To explore the synergistic effects of IL-33 and anti-PD-1 therapy.
Main Methods:
- Flow cytometry to quantify ILC2s, T cells, and PD-1 expression.
- Immunohistochemistry and immunofluorescence to detect IL-33 and ILC2 infiltration.
Main Results:
- Intra-tumoral ILC2s in LUAD are quiescent but activated by IL-33.
- IL-33 and anti-PD-1 combination therapy enhances anti-tumor immunity.
- This combination upregulates activated mature ILC2s (mILC2s), enhancing anti-PD-1 therapy.
Conclusions:
- ILC2s significantly contribute to anti-tumor responses in cancer immunotherapy.
- Targeting both ILC2s and T cells is a promising immunotherapy strategy.
Related Concept Videos
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K